Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.

Söderberg, Linda; Johannesson, Malin; Nygren, Patrik; Laudon, Hanna; Eriksson, Fredrik; Osswald, Gunilla; Möller, Christer; Lannfelt, Lars

Söderberg, Linda; Johannesson, Malin; Nygren, Patrik; Laudon, Hanna; Eriksson, Fredrik; Osswald, Gunilla; Möller, Christer; Lannfelt, Lars.

Afiliação

Söderberg L; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Johannesson M; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Nygren P; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Laudon H; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Eriksson F; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Osswald G; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Möller C; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Lannfelt L; BioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden. Lars.Lannfelt@pubcare.uu.se.

Neurotherapeutics ; 20(1): 195-206, 2023 01.

Article em En | MEDLINE | ID: mdl-36253511

Assuntos

Doença de Alzheimer; Peptídeos beta-Amiloides; Humanos; Doença de Alzheimer/tratamento farmacológico; Doença de Alzheimer/metabolismo; Peptídeos beta-Amiloides/metabolismo

Palavras-chave

Aducanumab; Amyloid-beta species; Gantenerumab; Lecanemab; Therapeutic antibodies

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Doença de Alzheimer Limite: Humans Idioma: En Revista: Neurotherapeutics Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google